Medical cannabis sales channels are facing obstacles in the United States. Still illegal at the federal standpoint, this market segment is dependent on sale outlets that developed out of the necessity to have some level of state government substance control. Doctors who prescribe marijuana for patients act as de facto gatekeepers, regulating distribution by providing it to those who “need” alternative treatments for medical conditions or to alleviate side effects versus those who “want” the marijuana for recreational use.
Various conditions are treated and the healthy advantages that are gained from the use of medical marijuana. Individuals benefit from the use of medical cannabis for pain management, seizures connected to epileptic episodes and other conditions, glaucoma, and a wide range of mental and neurological conditions. A report on ClinicalTrials.gov displays that there are a fair amount of open clinical studies that are currently being conducted to test the existence of health benefits in correlation to many medical symptoms associated with the use of marijuana.
There will need to be more substantial scientific investigations to show proper evidence to doctors that there are both conditions specific and complementary health advantages to be obtained through the use of marijuana in order to encourage them to prescribe marijuana to patient if allowed.
Though the medical marijuana industry wants to market complementary health advantages of marijuana to possible medical users through different outlets of media, then they, in theory, must get a government approved qualified health claim through the U.S. Food & Drug Administration.
Recreational use, on the other hand, is much simpler to market directly to possible users in places where it is legal to use marijuana for recreational reasons. There isn’t a dependence on using health reasons to push doctors to allow the access to potential marijuana users because marijuana distributors are allowed to sell their crop directly to those who bit “need” and “want” it.
Medical cannabis sales channels are facing obstacles in the United States. Still illegal at the federal standpoint, this market segment is dependent on sale outlets that developed out of the necessity to have some level of state government substance control. Doctors who prescribe marijuana for patients act as de facto gatekeepers, regulating distribution by providing it to those who “need” alternative treatments for medical conditions or to alleviate side effects versus those who “want” the marijuana for recreational use.
Various conditions are treated and the healthy advantages that are gained from the use of medical marijuana. Individuals benefit from the use of medical cannabis for pain management, seizures connected to epileptic episodes and other conditions, glaucoma, and a wide range of mental and neurological conditions. A report on ClinicalTrials.gov displays that there are a fair amount of open clinical studies that are currently being conducted to test the existence of health benefits in correlation to many medical symptoms associated with the use of marijuana.
There will need to be more substantial scientific investigations to show proper evidence to doctors that there are both conditions specific and complementary health advantages to be obtained through the use of marijuana in order to encourage them to prescribe marijuana to patient if allowed.
Though the medical marijuana industry wants to market complementary health advantages of marijuana to possible medical users through different outlets of media, then they, in theory, must get a government approved qualified health claim through the U.S. Food & Drug Administration.
Recreational use, on the other hand, is much simpler to market directly to possible users in places where it is legal to use marijuana for recreational reasons. There isn’t a dependence on using health reasons to push doctors to allow the access to potential marijuana users because marijuana distributors are allowed to sell their crop directly to those who bit “need” and “want” it.
MAPH Enterprises, LLC | (305) 414-0128 | 1501 Venera Ave, Coral Gables, FL 33146 | new@marijuanastocks.com
